Deleted Tweets From Scott Gottlieb, R-D.C.

RT @presidencia_cl: Ahora: Presidenta @mbachelet recibe al Secretario de Salud de Estados Unidos, Alex Azar, en el marco de la transmis… https://t.co/qXgYxpQpiK

#FDA is committed to helping facilitate the development of safe, effective treatments that can address the devastating impact from Alzheimer's. Our new guidance outlines more modern, efficient pathways for innovation in this area https://t.co/47niz5JjJk

RT @FDAOncology: Watch @FDAOncology Pazdur on importance of communication among all parties in expanded access https://t.co/F8nY97WFUB @reaganudall

#FDA’s new suite of policies on the development of drugs targeted to neurological diseases — including #ALS and Alzheimer’s — adopts modern, efficient scientific principles for advancing new medical innovation https://t.co/47niz5JjJk

#FDA shares details of key prescription drug promotion social science research it plans to conduct in the next year. Topics include a focus on effectiveness of disclosures and communications with health care providers https://t.co/YV96cGMPG5

RT @FDACosmetics: Using a sunless tanner or bronzer to get #SpringBreak ready? Unless it’s labeled with SPF, you’re not protected fro… https://t.co/CKGi468wGR

#FDA takes new steps to advance social science research surrounding how patients and health care providers understand prescription drug benefit and risk information in promotional materials to help inform our policies https://t.co/YV96cGMPG5

BioCentury: #FDA wants to expand accelerated approval pathway beyond traditional surrogate endpoints to include overall survival; a response to advances that make it increasingly possible to identify potential breakthroughs earlier in clinical development

RT @steveusdin1: Stretching accelerated approval... a response to advances in targeted drug development that are making it increasin… https://t.co/URd9rzZGZ7

RT @FDA_Track: FDA In Brief: FDA unveils research plan to inform policy, enforcement work related to prescription #drugpromotion https://t.co/xc58szFk4K

RT @FDAOncology: #FDA issued final #guidance for industry on BCG-Unresponsive Nonmuscle Invasive Bladder Cancer: Developing Drugs an… https://t.co/f6N6iCVxdW

#FDA Lays Out Plans for Future Research on Pharmaceutical Ads and Promotions https://t.co/q7h6paOstX

I commend @PresCancerPanel on today’s #CancerRxValue report.. #FDA will continue to do its part to ensure competition in the generics and biosimilar markets, which contributes to more affordable cancer medicines. https://t.co/lmyCQo6by5

#FDA is holding a Patient-Focused Drug Development meeting in April to allow individuals with opioid use disorder bring their voice to FDA and the drug development process. Help make this meeting a success by signing up to participate: https://t.co/kqkjUN

Today’s @PresCancerPanel #CancerRxValue report calls on all of us to do more for patients, who may be priced out of life-saving cancer treatments. #FDA is committed to fostering more competition, access to affordable medicines https://t.co/lmyCQo6by5

RT @ConsumerFed: Looking forward to @SGottliebFDA's keynote address at this year's National Food Policy Conference. #CFAFPC https://t.co/VjHf9Uuv5w

For #PFDD meeting, we’re interested patient views on: the impact opioid use disorder has on their health and well-being/daily life; experience with prescription and other treatments; challenges/barriers to accessing/using medication-assisted treatments: h

#PFDD meeting is part of efforts to promote innovation/access to treatment to help those w/an opioid use disorder. We’re devoting equal vigor to preventing new addiction and ensuring access to potentially lifesaving treatment for those currently addicted:

RT @RAPSorg: .@US_FDA Lays Out Plans for Future Research on #Pharma Ads and Promotions | #Regulatory Focus https://t.co/ay2FXlBeFY #FDA #pharmamarketing

Other #FDA efforts to promote innovation/access to opioid use disorder treatment include facilitating development of new meds & new forms of existing drugs that could have attributes better tailored to patient needs. We’re also tackling stigma that’s

RT @presidencia_cl: Ahora: Presidenta @mbachelet recibe al Secretario de Salud de Estados Unidos, Alex Azar, en el marco de la transmis… https://t.co/qXgYxpQpiK

#FDA is committed to helping facilitate the development of safe, effective treatments that can address the devastating impact from Alzheimer's. Our new guidance outlines more modern, efficient pathways for innovation in this area https://t.co/47niz5JjJk

RT @FDAOncology: Watch @FDAOncology Pazdur on importance of communication among all parties in expanded access https://t.co/F8nY97WFUB @reaganudall

#FDA’s new suite of policies on the development of drugs targeted to neurological diseases — including #ALS and Alzheimer’s — adopts modern, efficient scientific principles for advancing new medical innovation https://t.co/47niz5JjJk

#FDA shares details of key prescription drug promotion social science research it plans to conduct in the next year. Topics include a focus on effectiveness of disclosures and communications with health care providers https://t.co/YV96cGMPG5

RT @FDACosmetics: Using a sunless tanner or bronzer to get #SpringBreak ready? Unless it’s labeled with SPF, you’re not protected fro… https://t.co/CKGi468wGR

#FDA takes new steps to advance social science research surrounding how patients and health care providers understand prescription drug benefit and risk information in promotional materials to help inform our policies https://t.co/YV96cGMPG5

BioCentury: #FDA wants to expand accelerated approval pathway beyond traditional surrogate endpoints to include overall survival; a response to advances that make it increasingly possible to identify potential breakthroughs earlier in clinical development

RT @steveusdin1: Stretching accelerated approval... a response to advances in targeted drug development that are making it increasin… https://t.co/URd9rzZGZ7

RT @FDA_Track: FDA In Brief: FDA unveils research plan to inform policy, enforcement work related to prescription #drugpromotion https://t.co/xc58szFk4K

RT @FDAOncology: #FDA issued final #guidance for industry on BCG-Unresponsive Nonmuscle Invasive Bladder Cancer: Developing Drugs an… https://t.co/f6N6iCVxdW

#FDA Lays Out Plans for Future Research on Pharmaceutical Ads and Promotions https://t.co/q7h6paOstX

I commend @PresCancerPanel on today’s #CancerRxValue report.. #FDA will continue to do its part to ensure competition in the generics and biosimilar markets, which contributes to more affordable cancer medicines. https://t.co/lmyCQo6by5

#FDA is holding a Patient-Focused Drug Development meeting in April to allow individuals with opioid use disorder bring their voice to FDA and the drug development process. Help make this meeting a success by signing up to participate: https://t.co/kqkjUN

Today’s @PresCancerPanel #CancerRxValue report calls on all of us to do more for patients, who may be priced out of life-saving cancer treatments. #FDA is committed to fostering more competition, access to affordable medicines https://t.co/lmyCQo6by5

RT @ConsumerFed: Looking forward to @SGottliebFDA's keynote address at this year's National Food Policy Conference. #CFAFPC https://t.co/VjHf9Uuv5w

For #PFDD meeting, we’re interested patient views on: the impact opioid use disorder has on their health and well-being/daily life; experience with prescription and other treatments; challenges/barriers to accessing/using medication-assisted treatments: h

#PFDD meeting is part of efforts to promote innovation/access to treatment to help those w/an opioid use disorder. We’re devoting equal vigor to preventing new addiction and ensuring access to potentially lifesaving treatment for those currently addicted:

RT @RAPSorg: .@US_FDA Lays Out Plans for Future Research on #Pharma Ads and Promotions | #Regulatory Focus https://t.co/ay2FXlBeFY #FDA #pharmamarketing

Other #FDA efforts to promote innovation/access to opioid use disorder treatment include facilitating development of new meds & new forms of existing drugs that could have attributes better tailored to patient needs. We’re also tackling stigma that’s